Top
×
Hepatoma Res 2017;3:178-81.10.20517/2394-5079.2017.18© 2017 OAE Publishing Inc.
Open AccessCase Report

Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

See all authors and affiliations

1Department of Hepatology, National Liver Institute, Menoufia University, Shebin Elkom 32511, Egypt.

2Department of Community Medicine, National Liver Institute, Menoufia University, Shebin Elkom 32511, Egypt.

3Department of Clinical Pharmacology, Faculty of Pharmacy, Horus University, New Domiat 45633, Egypt.

Correspondence Address: Dr. Maha M. Elsabaawy, Department of Hepatology, National Liver Institute, Menoufia University, Shebin Elkom 32511, Egypt. E-mail: maha.ahmed@liver.menofia.edu.eg

    ...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License (http://creativecommons.org/licenses/by-nc-sa/3.0/), which allows others to remix, tweak and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

    Abstract

    Egypt had been vexed by the highest load of chronic hepatitis C in the world. It represents a vast market of the new direct-acting anti-viral drugs (DAAs); effectively treating chronic hepatitis C virus (HCV) infection. Eradication of HCV in Egypt has been challenged by the observed increased diagnosis of hepatocellular carcinoma (HCC) in relation to DAAs therapy. This is the first Egyptian report annotating to a series of sixteen chronic HCV infected cases without a diagnosis of HCC before DAAs therapy and unexpected development of HCC during or after completion of DAAs therapy.

    Introduction

    Hepatocellular carcinoma (HCC) is one of the most dreadful sequels of hepatitis C virus (HCV)-related cirrhosis.[1] New direct-acting antivirals (DAA) had successfully created a new era of HCV elimination.[2] However, their role in moderating the incidence of HCC in those patients is still questionable. Beyond the several observations of the proximity between DAAs therapy, and emerging HCC, many systematic reports have been sequentially reported.[3-5] The first one is from Barcelona reported that HCC recurrence in 27.6% of the studied patients after a median follow-up of 5.7 months. Notably, they achieved viral eradication and had no pretreatment evidence of residual HCC.[3] In the Italian cohort that included 59 patients with earlier HCC and 295 patients negative for HCC, the HCC recurred at a rate of 28.8%, while de novo HCC showed a lower rate (3.16%).[4] The French report that included 3 studies and 6,000 patients who received interferon (IFN)-free regimens had refuted the Spanish and Italian data. The researchers found no increased risk of developing de novo HCC and a relatively low risk for HCC recurrence.[5]

    Amelioration of HCV natural history is the anticipated post treatment target. Sustained virological responses (SVR) and their link to lessened HCV-related morbidity and mortality, including HCC had been interrogated since the era of IFN-containing regimens.[6] This conception has been already recalled in the new era of DAAs with evolving comparable perspectives.[7] This is the first report from Egypt; registering 16 primary HCC cases respective to DAAs therapy.

    Case report

    This report includes a series of 16 patients who were diagnosed as Child A HCV-related cirrhosis. They presented to National Liver Institute Hospital, Menofia University, Egypt, to receive care and management as inpatients in the Clinical Hepato-Gastroenterology Department.

    The patients were males except for 1 female and at their late fifties. They were diagnosed as having HCV infection during the least 4 years. Pre DAAs treatment evaluation, laboratory, endoscopic as well as tedious professional abdominal imaging [either abdominal ultrasound or computerized tomography (CT) scan] were available for all patients.

    All patients received IFN-free, sofosbuvir-based regimens. Sofosbuvir plus ribavirin was prescribed to 11 cases (68.8%), sofosbuvir/daclatasvir plus ribavirin were given to 3 patients (18.8%), 1 patient was given sofosbuvir plus daclatasvir (6.2%), and 1 patient (6.2%) had received sofosbuvir plus simeprevir. SVR at week 12 post treatment was achieved in 13 cases (81.25%).

    The patients had completed their treatment regimens, except 2 cases that developed drug-related complications, and stopped the treatment. Only 1 relapse was reported in this study group.

    The newer sonography and CT imaging in 2 cases as well as the remaining 14 patients had surprisingly unveiled presence of predominantly small HCC. The small-sized lesions added to the mean timing for HCC detection (4.19 ± 3.48 months post-treatment), and the pre-treatment compensated liver disease have suggested HCC occurrence rather than a continuation of pre-treatment lesions.

    Most of these new lesions were small; less than 3 cm in 12 patients (81%), 3-5 cm in 3 cases (18.8%), while 1 patient who was diagnosed with a lesion more than 5 cm. All these patients presented less than 1 year post-treatment (4.19 ± 3.48 months). The focal lesions were mainly cited in the right hepatic lobe (62.5%), 12.5% in the left lobe while multi-focal lesions were detected in 4 cases (25%) [Table 1].

    Table 1

    Descriptive demographic and bibliographic data of the studied patients (n = 16)

    Studied variablesMeanSD
    Age (years)56.636.79
    Duration of HCV infection (years)8.694.64
    Timing of HCC presentation post treatment (months)4.193.48
    GenderNumberPercent
     Males1593.8
     Females16.2
    HCV genotypingAll cases were genotype 4a
    Site of lesion(s) by ultrasound
     Right1062.5
     Left212.5
     Multifocal425.0
    Size of the lesion(s) (cm)
     Less than 31275.0
     3-5318.8
     More than 516.2
    Virological responses
     End of treatment1487.5
     Sustained responders1381.3
     Relapsers16.2
     Incomplete course212.5
    The DAAs’ regimens
     Sofosbuvir + ribvirin1168.8
     Sofosbuvir + simprevir16.2
     Sofosbuvir + daclatasvir318.8
     Sofosbuvir + daclatasvir + ribvirin16.2

    Malignant portal vein thrombosis was radiologically documented in 1 patient (6.25%). Significant biochemical derangements were reported following revelation of HCC. They were significant enough to transfer most of the affected patients from Child class A to Child C cirrhosis [Table 2].

    Table 2

    Descriptive laboratory data of the studied patients (n = 16)

    Laboratory investigationsBefore treatmentOn HCC diagnosis
    Total bilirubin (mg/dL)0.80 ± 0.664.84 ± 2.14
    Direct bilirubin (mg/dL)0.50 ± 0.201.82 ± 1.68
    AST (IU)88.40 ± 34.3479.00 ± 75.42
    ALT (IU)74.30 ± 23.6074.63 ± 52.12
    ALK (IU)45.00 ± 17.25172.25 ± 156.19
    GGT (IU)36.00 ± 12.0069.06 ± 72.15
    Serum albumin (mg/dL)3.40 ± 0.502.20 ± 0.88
    Hemoglobin (gm/L)12.30 ± 2.2011.81 ± 2.37
    WBCs (103/L)4.60 ± 6.108.63 ± 4.32
    Platelet (103/L)123.00 ± 32.50102.50 ± 45.10
    Prothrombin concentration (%)87.20 ± 12.4044.94 ± 25.47
    INR(s)1.20 ± 0.301.50 ± 0.46
    Serum HCV-RNA average levels (IU)517,229.10
    Serum AFP (ng/mL)20.00 ± 12.46479.46 ± 588.96

    Statistical analysis

    Statistical analysis was carried out using SPSS (Statistical Package for Social Science) program. Data was entered as numerical or categorical, as appropriate. Quantitative data was shown as mean, and SD, while qualitative data has been expressed as frequency and percent.

    Discussion

    Obviously, sofosbuvir is the principal DAA in the current case series and all published reports of HCC connected to DAAs.[8] However, the alleged link between DAAs in general, sofosbuvir or sofosbuvir related metabolites and carcinogenesis needs to be analyzed. Several theories were hypothesized to explain this proposed linkage; however, none of them had a robust proof of concept. DAAs induced HCV elimination with subsequent disturbance of immune functions and less anti-tumoral potency is the most proposed explanation for developing HCC. Also, deprivation of the hepatic microenvironment from the inflammatory scene containing endogenous IFN-inducible natural killer cell/cytotoxic T lymphocytes and many other antiviral tumor molecules; definitely has a pro-oncogenic effect.[9]

    The reported downregulation of IFN and IFN stimulated genes following dual sofosbuvir-ribavirin induced viral eradication might add another explanation.[10] In pre-clinical studies, IFN alpha had demonstrated activity against several tumor types including HCC. Many reports had demonstrated the beneficial effects of IFN alpha in reducing incidence of HCC in cirrhotic patients who achieved sustained virological response. van der Meer et al.[11] in their sizeable multinational study, with longstanding follow-up periods had proved the positive effect of post IFN SVR on reducing morbidity and mortality and in diminishing HCC incidence rates in HCV-related cirrhosis patients. They reported that only 4% of those who achieved SVR had experienced HCC development against 76% in those who didn’t.[11]

    A recent systematic review had examined the HCC incidence in 5 randomized controlled trials (RCTs) including 1,926 chronic hepatitis C (CHC) patients with cirrhosis or advanced fibrosis has concluded that IFN-treated CHC cirrhotic patients showed a lower HCC incidence than non-IFN-treated controls after 5-years follow-up.[12] The same review examined the outcome of antiviral treatments in 6 RCTs with a total of 374 HCV-related HCC patients who had received curative therapy for HCC. After a more than 25 months (median) follow-up, IFN-treated patients showed a lower recurrence rate of HCC, than non-IFN-treated controls.[12]

    Although the exact mechanism behind the anti-tumor properties of IFN has not been yet fully elucidated, it has been widely used for the treatment of numerous types of cancer, including certain hematological malignancies and solid tumors.[13] A recent in vivo study reported the IFN’s ability to synergize the apoptotic, autophagic as well as the anti-proliferative action of cisplatin.[14] Autophagy has been shown to be induced in HCC cell lines when treated with IFN-α2b in a dose-dependent manner.[15]

    Of note, autophagic cell death had been suggested as one of the anti-cancer actions of anti-cancer therapeutics.[16] Supporting these postulations was the recent study by Liang et al.[17] who concluded that treatment by pegylated IFN was associated with a lower HCC incidence than nucleos(t)ide analogues in chronic HBV infection. They described the oncogenic surface antigen truncation mutations to be detected in entecavir-treated patients with HCC but not in pegylated IFN-treated patients.[17]

    Unlike IFN, DAAs have neither anti-angiogenic nor anti-proliferative properties and have no effect on oncogenic buds that already would reside cirrhotic livers.

    For the time being, risk assessment for HCC should be rigorously undertaken before DAAs, and those at risk should have attentive surveillance during treatment and afterward. For people at risk, it is noteworthy to explain the importance of continued surveillance after HCV eradication. Also, physicians in the outreach clinics should know by heart that in HCV-positive patients, the risk of HCC is reaching higher figures compared with those eliminated the virus, yet sustained responders having advanced fibrosis are still at high HCC risk.

    Liver fibrosis has been proven to be regressive in some patients who eliminated the virus;[18] hence post treatment transient elastography would be beneficial in defining patients within the surveillance program. Moreover, surveillance programs had to be strengthened by predictive genetic as well as angiogenic HCC bio-markers.

    In conclusion, surveillance programs should be widely endorsed during and after DAAs therapy for patients at HCC risk, even for those who had been achieved HCV cure. Perhaps IFN still has a role -- using it as a backbone therapy might benefit patients at the highest risk of HCC.

    Declarations

    Authors’ contributions

    Idea and study design: E.A. Rewisha

    Collection of literature data: O. Elshaarawy, D.M. Elsabaawy

    Data analysis: A. Abdelah

    Clinical data collection, manuscript writing and critical revision: O.M. Alhaddad, M.M. Elsabaawy

    Financial support and sponsorship

    None.

    Conflicts of interest

    There are no conflicts of interest.

    Patient consent

    A written informed consent was obtained from all participants in the study.

    Ethics approval

    The study protocol was approved by the Institutional Review Board (IRB) and local ethical committee of the National Liver Institute, Menoufia University.

    References

    • 1. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol 2015;21:105-14.

      DOIPubMedPMC
    • 2. de Oliveria Andrade LJ, D'Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis 2009;1:33-7.

      DOIPubMedPMC
    • 3. Reig M, Mari-o Z, Perelló C, I-arrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.

      DOIPubMed
    • 4. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 2016;65:727-33.

      DOIPubMed
    • 5. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.

    • 6. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson SJ. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol 2017;66:19-27.

      DOIPubMed
    • 7. Bailly F, Pradat P, Virlogeux V, Zoulim F. Antiviral therapy in patients with hepatitis C virus-induced cirrhosis. Dig Dis 2015;33:613-23.

      DOIPubMed
    • 8. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol 2016;65:856-8.

      DOIPubMed
    • 9. Serti E, Park H, Keane M, O'Keefe AC, Rivera E, Liang TJ, Ghany M, Rehermann B. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN. Gut 2017;66:724-35.

      DOIPubMed
    • 10. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients. Hepatology 2015;61:790-801.

      DOIPubMedPMC
    • 11. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.

      DOIPubMed
    • 12. Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma. Sci Rep 2015;5:9954.

      DOIPubMedPMC
    • 13. Pasquali S, Mocellin S. The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma. Curr Med Chem 2010;17:3327-36.

      DOIPubMed
    • 14. Nelson MH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev 2015;263:90-105.

      DOIPubMedPMC
    • 15. Zhao J, Wang M, Li Z, Gao D, Cai Y, Chang J, Wang SH. Interferon-alpha-2b induces autophagy in hepatocellular carcinoma cells through Beclin1 pathway. Cancer Biol Med 2014;11:64-8.

    • 16. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013;4:e838.

    • 17. Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 2016;213:966-74.

      DOIPubMed
    • 18. Mandorfer M, Kozbial K, Schwabl PH, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer A, Reiberger TH, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692-9.

      DOIPubMed

    Article Access Statistics

    • Viewed: 2412
    • Downloaded: 281
    • Cited: 1

    Table of Contents